Eisai Files First Approval Application For Novel Breast Cancer Drug
This article was originally published in PharmAsia News
Executive SummaryEisai has filed an application for approval of one of its drugs for treating breast cancer in Switzerland. Eisai discovered and developed the compound used in its E7389 (halichondrin B) and plans to apply by the end of the year for approval in Japan, the rest of Europe and the United States. Eisai is also conducting clinical trials for using the drug in other types of cancer, including for treating prostate cancer in Europe and the United States. (Click here for more - a subscription may be required
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.